Axel Unterbeck, Ph.D.
Scientific Advisor
Oxford Bioscience Partners
Dr. Axel Unterbeck joined Oxford Bioscience Partners in 2005. Prior to joining Oxford, Dr. Unterbeck was President, Chief Scientific Officer, and Co-Founder at Memory Pharmaceuticals, Corp which achieved its initial public offering in April of 2004. Memory, which Dr. Unterbeck co-founded with Nobel Laureate Eric Kandel, M.D., was recently bought by Roche.

Dr. Unterbeck has over 23 years of R&D experience within the pharmaceutical and biotechnology industry.  He held various positions within central nervous system R&D at Bayer AG in Germany and the US, including Head of CNS/Dementia Research. Prior to joining Bayer AG, Dr Unterbeck was a member of the scientific team at the Institute for Genetics in Cologne which achieved the first full-length cloning of the human amyloid precursor protein (APP) gene implicated in Alzheimer’s disease.

He received his Ph.D. in Molecular Biology/ Genetics at the University of Cologne and his MS/BS degree in Biology at the University of Bonn.

"I am delighted to be working with Monica Coenraads and RSRT's translational effort.

At this critical point in Rett Syndrome research, the Trust is uniquely positioned to promote research towards multiple pathways for drug discovery and development and to identify new avenues for therapeutic intervention in this complex field.

RSRT's high standards and ability to engage extraordinary scientists and thinkers, combined with Monica's ten-year track record of progress in this field, should inspire the confidence and hope of Rett families everywhere."

- Axel Unterbeck, Ph. D.
Rett Syndrome Research Trust. © Copyright 2008